New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
08:15 EDTENZ, RHHBY, LMNX, LIFE, ILMN, HOLX, BDX, A, AFFX, ABT, SIEGYEnzo Biochem announces August 18 as date of Markman hearing in lawsuit
Enzo Biochem (ENZ) announced today that U.S. District Judge Leonard P. Stark has established August 18th as the date for a patent claim construction hearing, also called a Markman hearing, involving Enzo Life Science’s U.S. Patents Nos. 6,992,180, 7,064,197, and 8,097,405. The hearing will be held in Delaware District Court. One or more of these patents is asserted against Abbott Labs (ABT), Affymetrix (AFFX), Agilent (A), Becton Dickinson (BDX), Gen-Probe, Hologic (HOLX), Illumina (ILMN), Life Technologies (LIFE), Luminex (LMNX), Roche (RHHBY), and Siemens (SIEGY), and their related entities. At such a hearing, the Judge will be asked to issue rulings regarding the language and interpretation of Enzo's patents at issue in the case. Markman hearings are considered a key event in a patent lawsuit. The upcoming Markman ruling will define the property rights for the technologies that Enzo has invented. Such rulings often drive and inform many aspects of the litigation.
News For ENZ;ABT;AFFX;A;BDX;HOLX;ILMN;LIFE;LMNX;RHHBY;SIEGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 16, 2014
14:47 EDTRHHBYRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
13:13 EDTRHHBYRoche considers submitting Ebola test for emergency use approval, WSJ says
Subscribe for More Information
10:01 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:35 EDTRHHBYDiplomat announces contract to distribute Esbriet
Subscribe for More Information
09:21 EDTSIEGYSiemens signs two long-term wind service agreements in the U.S.
Subscribe for More Information
06:32 EDTAFFXAffymetrix and Ariosa Diagnostics sign multi-year prenatal test supply agreement
Subscribe for More Information
05:58 EDTRHHBYRoche sees FY14 core EPS targeted to grow ahead of sales
Subscribe for More Information
05:56 EDTRHHBYRoche reports 9 month revenue CHF34.76B vs. CHF34.87B last year
Roche CEO Severin Schwan said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets. We have had positive news from our product pipeline, including study results for Perjeta in breast cancer and a new combination therapy with Zelboraf in melanoma. The InterMune acquisition has also strengthened our portfolio with a new medicine, Esbriet for idiopathic pulmonary fibrosis, which has now been approved by the FDA. In Diagnostics, growth continues to be driven by the immunodiagnostics business and we have strengthened our molecular diagnostics portfolio with a new generation of testing systems.”
05:33 EDTILMNIllumina upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
October 15, 2014
15:45 EDTRHHBYFDA approves Esbriet to treat idiopathic pulmonary fibrosis
Subscribe for More Information
11:14 EDTSIEGYBayerischer Rundfunk says Siemens to reduce jobs at unit, Reuters says
Subscribe for More Information
10:48 EDTABTShire tanks with AbbVie calling board meeting over merger
Subscribe for More Information
08:52 EDTLMNXLuminex CEO PAtrick Baithrop retiring, succeeded by Nachum Shamir
Luminex President and CEO Patrick J. Balthrop, Sr. has retired. The board of directors has named Nachum "Homi" Shamir as President and CEO. Mr. Balthrop will continue to serve the company and its shareholders as a consultant to the Board and Mr. Shamir, and will be assisting in the transition through April 14, 2015.
06:32 EDTILMNIllumina to invest in three genomics industry startups
Illumina selected three startup companies for the inaugural Illumina Accelerator funding cycle. The companies are Encoded Genomics, EpiBiome and Xcell Biosciences. The Illumina Accelerator will provide selected startups with seed investment, business guidance, access to Illumina’s sequencing systems and reagents, and fully operational lab space in the San Francisco Bay Area during the six-month cycle.
October 14, 2014
13:05 EDTAAgilent sees FY15 revenue declining $20M-$30M due to NMR business closure
Subscribe for More Information
13:03 EDTAAgilent sees Q4 EPS 87c-91c, consenssus 89c
Subscribe for More Information
13:02 EDTAAgilent to close Nuclear Magnetic Resonance business
Subscribe for More Information
11:23 EDTRHHBYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
08:15 EDTILMNIllumina should report stronger than expected results, says Wedbush
Subscribe for More Information
October 13, 2014
08:04 EDTBDXBD acquires GenCell Biosystems
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use